Literature DB >> 17045179

Changes in plasma N-terminal proBNP levels and ventricular filling pressures during intensive unloading therapy in elderly with decompensated congestive heart failure and preserved left ventricular systolic function.

Giovanni Cioffi1, Luigi Tarantini, Carlo Stefenelli, Giordano Azzetti, Russo Marco, Sergio Carlucci, Francesco Furlanello.   

Abstract

BACKGROUND: Plasma B-type natriuretic peptide (BNP) levels depend on left ventricular (LV) filling pressures and correlate with the state of neurohormonal modulation in patients with congestive heart failure (CHF). In these subjects, therapy of decompensated CHF can determine acute changes in BNP levels. METHODS AND
RESULTS: We defined the sequential pattern of N-terminal (T) proBNP in elderly with decompensated CHF and preserved LV systolic function undergoing intensive unloading therapy, assessed the prevalence of patients who significantly reduced NTproBNP at the end of treatment, and verified the relations between changes in NTproBNP and ventricular filling pressures. NTproBNP was measured in 30 patients hospitalized for worsening CHF with LV ejection fraction >50% at admission and after 2 to 4 and 6 to 8 days from the start of treatment. Patients who exhibited a reduction in NTproBNP >35% from baseline to 8-day evaluation were defined as "responders." Twelve healthy subjects matched for age and sex were used as controls. NTproBNP was significantly higher in CHF patients than controls in all time points, to a greater extent in baseline evaluation (2982 [lower/upper quartile 1273/8146] versus 235 [150/280] pg/mL). A progressive, linear reduction of NTproBNP was detected in CHF patients during unloading. At Day 8, 18 patients (60%) resulted in "responders," whereas 12 (40%) were "nonresponders." The former could be predicted through higher pulmonary artery wedge pressure at baseline. Surprisingly, ventricular filling pressures similarly declined in responders and non responders. At Day 8, NTproBNP was yet 7-fold higher in CHF patients than controls.
CONCLUSION: Intensive unloading therapy is associated with a significant short-term reduction in NTproBNP in elderly with CHF and preserved LV systolic function. This behavior is progressive and linear during the first week and parallels a reduction in ventricular filling pressures which, however, does not differ between patients who significantly reduce NTproBNP and those who do not. Thus the short-term changes in NTproBNP during intensive unloading therapy in our patients do not depend only on the acute improvement in hemodynamic conditions.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17045179     DOI: 10.1016/j.cardfail.2006.06.003

Source DB:  PubMed          Journal:  J Card Fail        ISSN: 1071-9164            Impact factor:   5.712


  5 in total

1.  Spironolactone metabolite concentrations in decompensated heart failure: insights from the ATHENA-HF trial.

Authors:  Simon de Denus; Grégoire Leclair; Marie-Pierre Dubé; Isabelle St-Jean; Yassamin Feroz Zada; Essaïd Oussaïd; Martin Jutras; Michael M Givertz; Robert J Mentz; W H Wilson Tang; João Pedro Ferreira; Jean Rouleau; Javed Butler; Andreas P Kalogeropoulos
Journal:  Eur J Heart Fail       Date:  2020-04-01       Impact factor: 15.534

Review 2.  Nitroprusside in decompensated heart failure: what should a clinician really know?

Authors:  Cristina Opasich; Giovanni Cioffi; Alessandra Gualco
Journal:  Curr Heart Fail Rep       Date:  2009-09

Review 3.  Biomarkers in heart failure: the importance of inconvenient details.

Authors:  Wayne L Miller; Allan S Jaffe
Journal:  ESC Heart Fail       Date:  2015-11-25

4.  Natriuretic Peptide testing in primary care.

Authors:  Shafiq U Rehman; James L Januzzi
Journal:  Curr Cardiol Rev       Date:  2008-11

5.  Pharmacodynamic and Pharmacokinetic Profiles of Sacubitril/Valsartan (LCZ696) in Patients with Heart Failure and Reduced Ejection Fraction.

Authors:  Zhanna Kobalava; Yulia Kotovskaya; Oleg Averkov; Elena Pavlikova; Valentine Moiseev; Diego Albrecht; Priya Chandra; Surya Ayalasomayajula; Margaret F Prescott; Parasar Pal; Thomas H Langenickel; Pierre Jordaan; Iris Rajman
Journal:  Cardiovasc Ther       Date:  2016-08       Impact factor: 3.023

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.